Last reviewed · How we verify
Ticagrelor vs Clopidogrel
Ticagrelor vs Clopidogrel is a Small molecule drug developed by Fundación Investigación Sanitaria en León. It is currently in Phase 1 development.
Ticagrelor is a small molecule that acts as a negative allosteric modulator of the P2Y purinoceptor 12, a purinergic receptor involved in platelet activation. It is used to treat conditions such as Atrial Fibrillation, Percutaneous Coronary Intervention, ST-segment Elevation Myocardial Infarction, Left Main Coronary Artery Stenosis, and Acute Myocardial Infarction, among others.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ticagrelor vs Clopidogrel |
|---|---|
| Sponsor | Fundación Investigación Sanitaria en León |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation (NA)
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD (NA)
- TADCLOT- a Double Blind Randomized Controlled Trial (PHASE3)
- Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing (NA)
- Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor vs Clopidogrel CI brief — competitive landscape report
- Ticagrelor vs Clopidogrel updates RSS · CI watch RSS
- Fundación Investigación Sanitaria en León portfolio CI
Frequently asked questions about Ticagrelor vs Clopidogrel
What is Ticagrelor vs Clopidogrel?
Who makes Ticagrelor vs Clopidogrel?
What development phase is Ticagrelor vs Clopidogrel in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing